<DOC>
	<DOCNO>NCT02682264</DOCNO>
	<brief_summary>The primary objective study determine long-term safety CB-03-01 cream , 1 % applied twice daily additional nine month study participant acne vulgaris participated Phase 3 pivotal study total treatment 12 month .</brief_summary>
	<brief_title>An Open-Label , Long-Term Extension Study Evaluate Safety CB-03-01 Cream , 1 % Participants With Acne Vulgaris</brief_title>
	<detailed_description>This multicenter , open label , long-term extension study CB-03-01 cream , 1 % focus safety male female participant , 9 year old complete one Phase 3 pivotal study [ CB-03-01/25 CB-03-01/26 ] . Participants apply active medication ( CB-03-01 cream , 1 % ) twice daily entire face , designate investigator AND desire participant , truncal acne nine additional month treatment . Thus , overall participant expose CB-03-01 cream , 1 % total treatment 12 month ( 0 3 month Phase 3 pivotal study additional nine month long-term safety study ) . Participants treat facial acne per protocol nine month . Treatment truncal acne discuss investigator participant . Treatment face and/or trunk may discontinue if/when acne clear re-started if/when acne worsens , accord assessment investigator respective treatment area ( i.e. , face trunk ) . Participants ( approximately 600 ) roll Phase 3 pivotal study [ CB-03-01/25 CB-03-01/26 ] long-term , safety study order achieve least 300 participant on-study 6 month 100 participant on-study 12 month .</detailed_description>
	<mesh_term>Acne Vulgaris</mesh_term>
	<criteria>Participant successfully complete participation one Phase 3 pivotal study [ CB0301/25 CB0301/26 ] . Participant agree use effective method contraception throughout study , applicable . Participant provide write informed consent assent . Participant willing comply study instruction return clinic require visit . Participant pregnant , lactating , plan become pregnant study . Participant skin disease condition could interfere safety evaluation test product require use interfere topical systemic therapy . Participant condition , investigator 's opinion , would make unsafe unsuitable participant participate research study . Participant plan use investigational drug device participation study . Participant know hypersensitivity previous allergic reaction drug ingredient . Participant plan use restrict systemic and/or topical antiacne preparation medication study</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>acne</keyword>
</DOC>